Search Within

Neil Mukund Iyengar

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (13)
  3. Research Letter (1)
Groups
  1. Breast Medicine Service (43)
  2. Department of Medicine (43)
  3. Epidemiology and Biostatistics (43)
  4. Population Sciences Research Program (43)
  5. Solid Tumor Oncology Division (43)
  6. Survivorship Research (43)

More Groups

People
  1. Clifford Hudis (21)
  2. Chau Dang (20)
  3. Larry Norton (20)
  4. Sujata Patil (20)
  5. Shanu Modi (17)
  6. Jose Baselga (13)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (5)
  4. 2022 (7)
  5. 2021 (3)
  6. 2019 (3)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Blood (6)
  3. Cancer Research (5)
  4. Cancer (3)
  5. Clinical Lymphoma, Myeloma and Leukemia (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (16)
  2. American Society of Hematology (6)
  3. American Association for Cancer Research (5)
  4. Elsevier Inc. (5)
  5. Oxford University Press (3)
  6. Wiley Blackwell (3)

More Publishers

Results (43)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow-up
    Journal Article

    Wang, R.; Smyth, L. M.; Iyengar, N.; Chandarlapaty, S.; Modi, S.; Jochelson, M.; Patil, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Lyons, T.; Gucalp, A.; Arumov, A.; Patil, S.; Edelweiss, M.; Gorsky, M.; Troso-Sandoval, T. A.; Bromberg, J.; Sanford, R. A.; Iyengar, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: A systematic review and meta-analysis
    Journal Article

    Scott, J. M.; Zabor, E. C.; Schwitzer, E.; Koelwyn, G. J.; Adams, S. C.; Nilsen, T. S.; Moskowitz, C. S.; Matsoukas, K.; Iyengar, N. M.; Dang, C. T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution
    Meeting Abstract

    Argolo, D.; Friedman, M.; Smyth, L.; Iyengar, N.; Singh, J.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C.; Dang, C.
    Cancer Research (2016)

    Fulltext@MSK | Save